A Clinical Trial to Evaluate the Immunogenicity and Safety of sIPV in a ‘1+2’ Sequential Schedule With bOPV in Infants

Poliomyelitis

A Study to Evaluate Pharyngeal Immunity to Poliovirus Type-2 Effect of Digital Payment to Campaign Health Workers on Vaccination Coverage Community Engagement and Conditional Incentives to Accelerate Polio Study of a Novel Type 3 Oral Poliomyelitis Vaccine in Panama Study of a Novel Type 1 Oral Poliomyelitis Vaccine in Bangladesh Assessing Immunogenicity of Intramuscular Sabin Inactivated Poliovirus Vaccine and Non-inferiority of Intradermal Fractional Inactivated Poliovirus Vaccine A Safety Study of Sabin Inactivated Poliovirus Vaccine in Infants Study to Evaluate Eupolio(IPV)’s Safety, Long-term Protective Effect and Boosting Effect of One Booster Dose in the Three Primary Vaccination Plus Boosting Schedule, and Protective Effect in the Schedule With Bivalent OPV in Infants Safety of Sabin Inactivated Poliovirus Vaccine in Adults, Children and Infants and Lot Consistency Immunogenicity, and Safety of the msIPV in 2 Months Old Infants Intradermal Fractional Dose IPV (fIPV) in Combination With dmLT Physical Activity in People With Sequelae of Poliomyelitis Evaluation of the Immunogenicity and Safety of Concomitant Administration of Novel Oral Polio Type 2 Vaccine and Bivalent Oral Polio Vaccine Evaluation of Safety and Immunogenicity of Inactivated Adjuvanted Polio Vaccine in Comparison With Licensed Inactivated Poliovirus Vaccine Observational Program, Double-blind, Placebo-controlled to Study the Preventive Efficacy of the BiVac Polio Vaccine Against the Incidence of Acute Respiratory Infections, Including COVID-19 Study to Evaluate Safety and Immunogenicity of nOPV2 at Different Intervals in Infants An Immunity Persistence Study of Sabin Inactivated Poliovirus Vaccine(Vero Cell) After Four Doses Clinical Trial of Novel OPV2 Vaccine Cross-neutralization Capacity of Immune Serum From Different Dosage of Sabin Inactivated Poliovirus Vaccine Immunization A Study on Immunity Duration Against Polio Over 18 Months Infants After 2 or 3 Primary Doses Sabin IPV in China nOPV2 and bOPV Trial Immunogenicity and Safety of the Booster Dose of Polio Vaccine With Different Primary Sequential Schedules in China A Phase 2 Study to Evaluate the Safety and Immunogenicity of Two Oral Poliovirus Vaccine Candidates Study of Novel Types 1 and 3 Oral Poliomyelitis Vaccines Evaluation of the Persistence of the Immunity in 4-year-old Children Previously Immunised With IPV-Al AJV (Picovac®) by Measuring the Response to an Additional Dose of IPV-Al AJV Effect of Lactoferrin on Polio Seroconversion Effect of Ankle-foot Orthoses on Balance Confidence Safety and Immunogenicity of a Sabin Inactivated Poliovirus Vaccine (Phase Ib) Safety Study of a Single Dose of Monovalent High-dose Inactivated Poliovirus Type 2 Vaccine (m-IPV2 HD) in Infants Early in Life Safety and Immunogenicity of a Sabin Inactivated Poliovirus Vaccine Comparison of Immunity Following IPV Versus fIPV: a Community Based Randomized Controlled Trial in Pakistan OPV Transmissibility in Communities After Cessation of Routine OPV Immunization A Clinical Trial to Evaluate the Immunogenicity and Safety of sIPV in a “2+1″Sequential Schedule With bOPV in Infants A Clinical Trial to Evaluate the Immunogenicity and Safety of sIPV in a ‘1+2’ Sequential Schedule With bOPV in Infants Fractional Inactivated Poliovirus Vaccine Booster and Rotavirus Study Quality of Life in Adult Neurological Patients Immunogenicity and Safety Evaluation of Different Sequential Immunization Strategies by Sabin IPV and bOPV in Chinese Infants Assessment of Poliovirus Type 2 Immunogenicity of One and Two Dose Schedule With IPV and fIPV When Administered at 9-13 Months of Age in Bangladesh Studies of the Safety and Immunogenicity of a Sabin Inactivated Poliovirus Vaccine Immunogenicity of Intramuscular and Intradermal IPV Comparison of Immunogenicity of Inactivated Poliovirus Vaccine (IPV) Administered Intramuscularly or Intradermally Monovalent Oral Poliovirus Vaccine Type 1 Intestinal and Humoral Immunity Study An Immunogenicity and Safety Study of Sabin Inactivated Poliovirus Vaccine (Vero Cell) in 2-month-old Infants Immunogenicity and Safety of Booster Dose of PoliorixTM Vaccine in Previously Vaccinated Toddlers Sero-conversion Study for a Two-dose Schedule of Sabin IPV in China Immunogenicity and Safety Study of GlaxoSmithKline Biologicals’ Poliorix™ Vaccine Duration of IPV Priming and Antibody Decay A Campaign-based ID fIPV Administration Trial Intestinal and Humoral Immunity of Sequential Polio Vaccination Schedules Immunogenicity of 1 or 2 Doses of bOPV in Chilean Infants Primed With IPV Vaccine Immunogenicity of Monovalent Type 2 Oral Poliovirus Vaccine Randomized Clinical Trial to Evaluate Immunogenicity and Safety in Mexicans Newborns Evaluation of Integrating MIYCN Interventions in Existing CGPP of PCI A Study to Evaluate Immunogenicity of Intramuscular Full-Dose and Intradermal Fractional Dose of IPV Inactivated Poliovirus Vaccine (IPV) With or Without dmLT Challenge Study in Healthy Adults A Study of Immunogenicity and Seroconversion With Sabin IPV Schedules in China. Immunogenicity of Intramuscular Inactivated Poliovirus Vaccine Serological Survey on Monitoring the Positive Rate After Vaccination of Inactivated Polio Vaccine Clinic Trial to Evaluate the Safety and Immunogenicity by Different Sequential Schedules of bOPV and IPV Persistence of IPV Immunity Evaluation of Buffer on Immune Response to Oral Polio Vaccine (OPV) in Bangladesh Safety and Immunogenicity of Adjuvanted Reduced Dose Inactivated Polio Vaccine in 2, 4, 6 Months of Age Safety and Immunogenicity of 1 or 2 Doses of IPV in Latin American Infants Primed With Bivalent OPV Vaccine Safety and Immunogenicity of Adjuvanted Reduced Dose Inactivated Polio Vaccine Given at 6, 10, 14 Weeks and 9 Months Pakistan Short Interval mOPV1 Compared With Standard Interval mOPV1 and bOPV 1,3 3 Adjuvated Reduced Dose IPV-Al SSI and Non-adjuvated Full Dose IPV SSI Given as Primary Vaccinations to Infants Phase 1 Novel Live Attenuated Serotype 2 Oral Polio Vaccine Study in IPV Primed Adults Randomized Controlled Trial for Immunogenicity and Safety Evaluation of Bivalent Types 1 and 3 Oral Poliovirus Vaccine Safety and Reactogenicity of GlaxoSmithKline (GSK) Biologicals’ IPV Vaccine (PoliorixTM) in Toddlers Safety and Immunogenicity of a New Inactivated Poliovirus Vaccine in Infants Study of SP059 Given Subcutaneously as a Three-dose Primary and Booster Vaccination in Infants in Japan Trail To Evaluate the Immune Effects of Primary and Booster Immunizations With Poliovirus Vaccine Lot-consistency Clinical Trial of Sabin Strain Inactivated Polio Vaccine A Study to Evaluate Immunogenicity of Various Schedules of Inactivated Polio Vaccine Environmental Surveillance (ES) for Polio and AMR Using the TaqMan Array Card Immunogenicity and Safety of Adjuvanted Reduced Dose Inactivated Polio Vaccine Given as a Booster at Age 15-18 Months Safety and Immunogenicity of IPOVAC in Young Children Polio End-game Strategies – Poliovirus Type 2 Challenge Study A Post-marketing Safety Study of GSK Bio IPV Vaccine (PoliorixTM) in Korean Children Phase 1 Study on the Safety and Reactogenicity of a Single Dose of Monovalent High-dose Inactivated Poliovirus Type 2 Vaccine (m-IPV2 HD) Given Intramuscularly Compared to Standard Trivalent Inactivated Poliovirus Vaccine (IPV) in Healthy Adults IPV-102 Safety, Tolerability and Immunogenicity of TAK-195 in Healthy Infants, Toddlers and Adults Polio NID and Routine EPI Integration Trial Pakistan Safety and Reactogenicity of GSK Biologicals’ Inactivated Poliomyelitis Vaccine (IPV) (Poliorix) in Infants Immunogenicity and Safety of a Fractional Booster Dose of IPV Intradermally Versus Full Dose Intramuscularly A Study to Evaluate the Safety and Immunogenicity of Monovalent OPV2 in Children Aged 1 to 5 Years in Lithuania Diarrhea and Bivalent Oral Polio Vaccine Immunity Comparison of Immune Response Using 2 Vaccination Schedules Using Inactivated Polio Vaccine Evaluation of Safety, Reactogenicity and Immunogenicity of Fractional-dose Inactivated Polio Vaccine (fIPV) Given Intradermally With Double Mutant Enterotoxigenic Escherichia Coli Heat Labile Toxin (dmLT) Adjuvant Consistency Study for Three Commercial Lots of Inactivated Poliomyelitis Vaccine Made From Sabin Strain Safety and Immunogenicity of a New Inactivated Polio Vaccine in Healthy Adults Effect of Zinc Supplementation on Response to Oral Polio Vaccine in Infants in Pakistan Immunogenicity of Inactivated and Live Polio Vaccines To Develop, Implement and Evaluate the Polio Demonstration Project Comprising of a Community Based Intervention Package for Polio Eradication in Pakistan A Study of the Safety of IMOVAX Polio™ in China Inactivated Poliomyelitis Vaccine Made From Sabin Strain A Clinical Study to Evaluate the Safety and Immunogenicity of Inactivated Poliomyelitis Vaccine in Healthy Infants Immunogenicity and Safety of Fractional Doses of IPV Intradermally vs Full Doses Intramuscularly A Study to Evaluate Safety and Immunogenicity of tOPV in 1 to 5 Years and at 6 Weeks of Age A Safety Study of IMOVAX Polio Vaccine in Selected Cities in China Study of IMOVAX POLIO® Subcutaneous as a Booster Vaccine in Pre-school Age Children in Japan Immunogenicity and Safety of Imovax Polio in Chinese Infants Compared to Local OPV The Clinical Trial Protocol for the Inactivated Poliomyelitis Vaccine Made From Sabin Strains (IPV) Immunogenicity and Safety of Liquid Bivalent Oral Poliomyelitis Vaccine Safety of Imovax Polio in Chinese Infants and Children Sequential Inactivated Poliomyelitis Vaccine Followed by Oral Poliomyelitis Vaccine Versus Oral Poliomyelitis Vaccine The Immunogenicity and Safety of Live Attenuated Poliomyelitis Vaccine (Human Diploid Cell) The Clinical Trial Protocol for the Inactivated Poliomyelitis Vaccine Made From Sabin Strains(Sabin IPV) The Clinical Trial Protocol for the Inactivated Poliomyelitis Vaccine Made From Sabin Strains